Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade

Matthew G. Mei, Lu Chen, Sandrine Puverel, L. Elizabeth Budde, Swetha Kambhampati, Shari Daniels, Bev Dunning, Melissa Banez, Larry W. Kwak, Alex F. Herrera

Blood (2023) 142 (Supplement 1): 1697.

https://doi.org/10.1182/blood-2023-190753

Published: 2023

Journal Articles

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

Han-Yu Cao, Lu-Lu Chen, Chao-Ling Wan, Xiao-Hui Hu, Bing Wu, Li Yang, Li Wang, Yang Zhang, De-Pei Wu, Hai-Ping Dai, Hao Zhang, Shengli Xue

Blood (2023) 142 (Supplement 1): 1501.

https://doi.org/10.1182/blood-2023-179733

Published: 2023

Journal Articles

Safety, Efficacy and T-Cell Predictive Biomarkers in a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey P. Shouse, Leslie L. Popplewell, Alex Muir, Tanya Siddiqi, Alex F. Herrera, Olga Danilova, Sandrine Puverel, Lili Wang, Adam S Kittai, Lu Chen, Matthew S Davids, Alexey Danilov

Blood (2023) 142 (Supplement 1): 1730.

https://doi.org/10.1182/blood-2023-182559

Published: 2023

Journal Articles

CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)

John H. Baird, Marissa Morales Del Real, Joo Y. Song, Geoffrey P. Shouse, Alexey Danilov, Alex F. Herrera, Leslie L. Popplewell, Steven T. Rosen, Jennifer Davis, Baishakhi Barva, Lu Chen, Larry W. Kwak, Stephen J. Forman, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 4840.

https://doi.org/10.1182/blood-2023-182456

Published: 2023

Journal Articles

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine M. Zain

Blood (2023) 142 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2023-188053

Published: 2023

Journal Articles

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

L. Elizabeth Budde, Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Swetha Kambhampati, Alan Macias, Teresa Kim, Sylvia Dulan, Baishakhi Barva, Sandrine Puverel, Katrin Tiemann, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak

Blood (2023) 142 (Supplement 1): 221.

https://doi.org/10.1182/blood-2023-183032

Published: 2023

Journal Articles

A Phase II Study of Intermittent Duvelisib Dosing in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Geoffrey P. Shouse, Lu Chen, Tanya Siddiqi, Alex Muir, Jennifer R. Brown, Stephen E Spurgeon, Alexey Danilov

Blood (2023) 142 (Supplement 1): 6531.

https://doi.org/10.1182/blood-2023-182543

Published: 2023

Journal Articles

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood (2023) 142 (16): 1359–1370.

https://doi.org/10.1182/blood.2023020485

Published: 2023

Includes: Supplemental data

Journal Articles

Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma

Swetha Kambhampati, Matthew Mei, Lu Chen, Sandrine Puverel, Robert Chen, Leslie L. Popplewell, Liana Nikolaenko, Lacolle Peters, Saro H. Armenian, Larry W. Kwak, Steve T Rosen, Stephen J Forman, Alex F. Herrera

Blood (2022) 140 (Supplement 1): 9418–9419.

https://doi.org/10.1182/blood-2022-157623

Published: 2022

Journal Articles

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 1065–1067.

https://doi.org/10.1182/blood-2022-165699

Published: 2022

Journal Articles

A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey Shouse, Tanya Siddiqi, Leslie L. Popplewell, Alexandra Muir, Ivana Melgar, Kirsten Orand, Brandy Gonzalez, Sandrine Puverel, Lili Wang, Adam S Kittai, Lu Chen, Matthew S. Davids, Alexey V Danilov

Blood (2022) 140 (Supplement 1): 6633–6634.

https://doi.org/10.1182/blood-2022-160157

Published: 2022

Journal Articles

A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

Alexey V Danilov, Alexandra Muir, Ivana Melgar, Sandrine Puverel, Peter Sportelli, Hari P. Miskin, Lu Chen, Geoffrey Shouse

Blood (2022) 140 (Supplement 1): 3633–3634.

https://doi.org/10.1182/blood-2022-159805

Published: 2022

Journal Articles

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood (2022) 139 (25): 3605–3616.

https://doi.org/10.1182/blood.2022015423

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Pallawi Torka, Swetha Kambhampati, Alexandra Muir, Kirsten Orand, Lynne Smith, Alex F. Herrera, Lionel Lewis, Francisco J. Hernandez-Ilizaliturri, Lu Chen, Alexey V. Danilov

Blood (2021) 138 (Supplement 1): 2433.

https://doi.org/10.1182/blood-2021-146345

Published: 2021

Journal Articles

A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey Shouse, Tanya Siddiqi, Leslie L. Popplewell, Alexandra Muir, Ivana Melgar, Brandy Gonzales, Kirsten Orand, Sandrine Puverel, Lili Wang, Adam S Kittai, Lu Chen, Matthew S. Davids, Alexey V. Danilov

Blood (2021) 138 (Supplement 1): 3558.

https://doi.org/10.1182/blood-2021-149320

Published: 2021

Journal Articles

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Alex F. Herrera, Jasmine Zain, Kerry J. Savage, Tatyana A. Feldman, Jonathan E Brammer, Lu Chen, Leslie L. Popplewell, Lihua E Budde, Matthew Mei, Lori A. Leslie, Ranjit Nair, Chitra Hosing, Lacolle Peters, Stephen J Forman, Steven T. Rosen, Larry W. Kwak, Swaminathan P Iyer

Blood (2021) 138 (Supplement 1): 133.

https://doi.org/10.1182/blood-2021-151105

Published: 2021

Journal Articles

Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade

Alex F. Herrera, Lu Chen, L. Elizabeth Budde, Saro Armenian, Liana Nikolaenko, Robert Chen, Shari Daniels, Neena Kennedy, Lacolle Peters, Steven T. Rosen, Stephen J Forman, Leslie L. Popplewell, Larry W. Kwak, Matthew Mei

Blood (2021) 138 (Supplement 1): 234.

https://doi.org/10.1182/blood-2021-150031

Published: 2021

Journal Articles

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-136384

Published: 2020

Journal Articles

Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-137258

Published: 2020

Journal Articles

Genomic Characterization of Diffuse Large B-Cell Lymphoma Transformation from Nodular Lymphocyte Predominant Hodgkin Lymphoma

Joo Y. Song, MD, Caoimhe Egan, Alyssa Bouska, PhD, Weiwei Zhang, PhD, Qiang Gong, Girish Venkataraman, MD MBBS, Alex F. Herrera, MD, Lu Chen, PhD, Rebecca Ottesen, Joyce Niland, PhD, Victoria Bedell, Maria Valle-Catuna, Joyce Murata-Collins, PhD, Dennis D. Weisenburger, MD, Javeed Iqbal, PhD, Elaine S. Jaffe, MD, Wing C. Chan, MD

Blood (2019) 134 (Supplement_1): 1486.

https://doi.org/10.1182/blood-2019-125095

Published: 2019

NARROW

The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

Safety, Efficacy and T-Cell Predictive Biomarkers in a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

A Phase II Study of Intermittent Duvelisib Dosing in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Genomic Characterization of Diffuse Large B-Cell Lymphoma Transformation from Nodular Lymphocyte Predominant Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only